

## www.FirstRanker.com

## HEMATOLOGY PAPER-I

HEM/D/17/48/I

Time: 3 hours Max. Marks: 100

• Attempt all questions in order.

DECEMBER 2017

- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space
- Answer all the parts of a single question together.
- Start the question to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

## Write short notes on:

1.	<ul> <li>a) Vitamin B<sub>12</sub> metabolism</li> <li>b) Role of Vitamin B<sub>12</sub> levels in diagnosis of B<sub>12</sub> deficiency and pitfalls</li> <li>c) Clinical manifestations of vitamin B<sub>12</sub> deficiency</li> <li>d) Non-megaloblastic macrocytic anemia and its causes</li> </ul>	4+3+3
2.	Hemophilia: a) Causes of acquired hemophilia b) Eliciting joint abnormalities c) Prenatal diagnosis of hemophilia	3+4+3
3.	Angiogenesis:  a) Its role in hematologic malignancies b) Anti-angiogenic drugs in treatment of hematologic malignancies c) Markers of angiogenesis	3+4+3
4.	AML: a) Molecular markers affecting prognosis of AML b) FLT3 Inhibitors c) AML with related myelodysplasia	4+3+3
5.	<ul><li>CART cells in Pediatric ALL:</li><li>a) Role of therapy in Pediatric ALL</li><li>b) How are they formed?</li><li>c) What lab facilities are required for generating and using CART cells in patients?</li></ul>	4+3+3
6.	Autoimmune hemolytic anemia (AIHA):  a) Management of warm type of AIHA. b) Methods of detection of auto-antibodies against RBC c) Coomb's negative auto immune hemolytic anemia	4+3+3



DECEMBER 2017

## www.FirstRanker.com

7.	<ul><li>a) Compensation in clinical trials</li><li>b) Role of sponsors in clinical trial</li><li>c) Salient features of Phase I, II and III clinical trials.</li></ul>	4+3+3
8.	<ul><li>a) Growth factors in normal hematopoiesis</li><li>b) Microenvironment in acquired aplastic anemia</li><li>c) Hematopoietic stem cell</li></ul>	3+4+3
9.	Minimal residual disease in ALL: <ul><li>a) What is minimal residual disease?</li><li>b) How is it detected?</li><li>c) How does treatment alter based on MRD?</li></ul>	3+4+3
10.	<ul><li>a) What are T-reg cells and how are they picked up?</li><li>b) What is their role in ITP?</li><li>c) Describe in brief dendritic cells</li></ul>	4+3+3

\*\*\*\*

MANN FIRST Ranker COM